NEWS

Today, three of the leading voices for obesity care are releasing new guidance for obesity medicines in ongoing therapy. The Obesity Society, Obesity Medicine Association, and Obesity Action Coalition all came together in support of this important new guidance. Alongside its publication in the journal Obesity, Beverly Tchang and Donna Ryan offer a “humbling call […]

World Obesity Day arrives today in a moment when the world feels inflamed. Headlines with images of conflict and human suffering suggest whole regions spinning into chaos. In this context, concerns about the global harm of obesity can seem disconnected from realities of the day. It is not. In fact, the global harms of obesity […]

Obesity Care Week is well under way, so it’s time to take a minute to reflect upon how we frame obesity and how that matters for everyone’s health. It is instinctive to frame obesity as an issue of weight. But it is also utterly false. Though excess weight is the most prominent and visible symptom […]

Obesity Care Week (March 2–6, 2026) begins today. This is a moment when advocates, clinicians, and people living with obesity unite around a simple but profound mission: to change the way society cares for – and about – obesity. But this year, let’s be honest about the scarcity of actual caring in obesity care. We […]

What unintended consequences might result from the new, upside-down food pyramid that our quixotic health secretary is touring the country to promote? One ironic twist will almost surely be a proliferation of ultra-processed protein foods. Yes, the guidelines advise to “eat real food.” But they also tell us to “prioritize protein foods at every meal.” […]

In December 2025, the Centers for Medicare & Medicaid Services announced something that once seemed politically out of reach: a pathway to meaningful Medicare and Medicaid coverage for obesity medications. And now, the details of how CMS will make these important medicines available in Medicare are coming into focus. The BALANCE Model At the center […]

In Lancet yesterday, Julio Rosenstock and colleagues published the results of a head-to-head comparison of orforglipron versus oral semaglutide in adults with type 2 diabetes and a BMI greater than 25. Headlines would have you believe this was a clear win for orforglipron over semaglutide. But it’s not quite that simple. The Study Details The […]

The hearing yesterday for the person nominated to become “America’s top doctor” reminds us of the low ebb we have reached in trust. Casey Means, this administration’s nominee for Surgeon General, tells us: “Trust yourself, not your doctor.” In fact, she wrote a whole book chapter advising this. Will this advice resonate with Americans? We […]

Novo Nordisk yesterday announced a roughly 50% cut in list prices for their popular GLP-1 agonists, Ozempic and Wegovy. Those cuts will be effective ten months from now, in January 2027. This is largely a signal to the marketplace and an acknowledgment of the fading fiction of inflated GLP-1 list prices. It has been a […]

Novo Nordisk unveiled the results of a commercially risky study of CagriSema for obesity yesterday and it was another tough break for Novo Nordisk. The study aimed to prove that – at worst – this next generation combination obesity drug is as good as tirzepatide. There was a slim hope was that it might prove […]